2012

Fall 2012
To read PDF, click here

1. On a Darkling Plain -- The Years of Despair
   Before the discovery of HAART.
   By Mark Harrington
2. Only Stronger U.S. Leadership Can End the AIDS Epidemic
   Existing treatment and prevention techniques could prevent millions of new HIV infections and deaths from AIDS -- but only if Obama sustains funding.
   By Mark Harrington

Spring 2012
To read PDF, click here

1. TAG at 20: Early Campaigns
   Reforming NIH AIDS research, boosting the budget and revitalizing the basic science of HIV infection.
   By Mark Harrington
2. The Odyssey of Therapeutic Vaccines for HIV
   By Richard Jefferys
3. What You Don't Know, You Can Sell
   Merck's cavalier attitude towards the welfare of HIV/HCV coinfected patients.
   By Tracy Swan
4. Does Obama's 2013 Budget Herald the End of PEPFAR?
   Devastating funding proposal undermines the global fight against AIDS.
   By Coco Jervis

2011

Fall 2011
To read PDF, click here

1. A Golden Decade of Antiretroviral Drug Development
   Success rate for new ARVs entering phases II-III surpassed 32% from 2003-2011; U.S. ADAP prescribing practices closely match recent ARV guidelines.
   By Polly Clayden and Mark Harrington
2. Cure Research Momentum Accelerates
   By Richard Jefferys
3. What We Need to Cure AIDS?
   By Mark Harrington

Summer 2011
To read PDF, click here

1. Julie Davids Reflects on CHAMP and the Future of HIV Prevention Justice
   Interview with veteran HIV prevention and social justice activist Julie Davids.
2. Moving an Exciting New TB Diagnostic From Policy to Practice
   By Javid Syed
3. Vaccine Breakthrough Comes With Caveats
   By Richard Jefferys
4. Clinical Trials Will Play a Vital Role in Charting the Path to an HIV Cure

Winter 2011
To read PDF, click here

1. The Past, Present and Future of HIV Microbicide Research Advocacy
   An interview with Polly Harrison, founder of the Alliance for Microbicide Development.
2. The First New Tuberculosis Drug in Decades: Promise and Challenges
3. HIV/AIDS Clinical Trials Network to Take on New Research Priorities Under Severe Funding Constraints
   By Coco Jervis
4. Microbicide Field Wrestles With the Implications of Success -- an Update

2010

Autumn 2010
To read PDF, click here

1. Reinvigorating the Search for a Cure
   By Richard Jefferys
2. Microbicide Field Wrestles With the Implications of Success
   By Richard Jefferys and Scott Morgan
3. Access to Hepatitis C Treatment: A Global Movement Gains Momentum
   By Tracy Swan
4. Deadly Economics Threaten Progress to Global Health Goals
   By Coco Jervis and Sue Perez
5. National Institutes of Health Donates Protease Inhibitor Patent to UNITAID Medicines Patent Pool
   By Mark Harrington
6. AIDS Drug Assistance Program in Crisis

Summer 2010
To read PDF, click here

1. Inflammatory Debate Over When to Start
   By Richard Jefferys
2. A New Start for an Old Movement
   The making of the HIV Research Catalyst Forum.
   By Lei Chou and Coco Jervis
3. Can More People Be Put on ART Without Increased Cost?
   By Scott Morgan
4. What U.S. Health Care Reform Means for People With HIV
   Slow implementation for needed changes.
   By Sue Perez and Coco Jervis

Winter 2010
To read PDF, click here

1. World Health Organization HIV Treatment Guidelines Evolve
   Safer and more effective drug combinations included in new guidelines.
   By Mark Harrington
2. NIAID Workshop: Elimination of HIV Reservoirs
   By Richard Jefferys
3. Two New Classes of TB Drugs -- the First in 40 Years -- Advance Through Phase II Studies
   After 40 years of scientific stagnation, it is beginning to be an exciting time in tuberculosis treatment research.
   By Claire Wingfield
4. As With HIV Treatment, Botswana Leads the Way With TB Prevention
   BOTUSA study strongly supports continuous preventive IPT for people with HIV.
   By Javid Syed
5. TAG Goes to Cuba
   Cuba boasts model health outcomes but at what costs to human rights?
   By Coco Jervis
6. Do The Right Thing
   Eliminating racial disparities in viral hepatitis drug development.
   By Lei Chou and Tracy Swan, presented at HEP DART 2009
7. President Obama's Disappointing 2011 Budget Presents Sharp Gap Between Needs and Funds Available
   Negligible increases for AIDS, TB, viral hepatitis treatment and research.
   By Sue Perez
8. Tools for TB Advocacy

2009

Summer 2009
To read PDF, click here

1. AIDS Funding Backlash
   A conversation with Sue Perez and Gregg Gonsalves.
   By Scott W. Morgan
2. The HIV Entry Ban: What's Next?
   A talk with Nancy Ordover.
   By Bob Huff
3. A Long-Term Survivor
   The pioneering MACS cohort.
   By Gregg Gonsalves
4. State AIDS Drug Assistance Program (ADAP) Hepatitis Coverage (PDF)
5. Two New TAG Publications
   Research funding gaps revealed

Winter 2008/2009
To read PDF, click here

1. TAG Sponsors "Cure Meeting"
2. TAG Remembers Paul Newman

2008

Summer 2008
To read PDF, click here

1. Sixteen Radical Steps to End the AIDS Epidemic
   By Mark Harrington
2. Notes on the 2008 International AIDS Conference
   By Bob Huff
3. Meet the Activists: Battling the TB/HIV Epidemic Through Community Action
4. A Chimpanzee Tale: Why Are They Resistant to AIDS?
   By Richard Jefferys
5. The Shrinking of PAVE100: Large-Scale Vaccine Trial Nixed
   By Richard Jefferys

Winter 2008
To read PDF, click here

1. Merck HIV Vaccine Trial Results: Hopes Dim for Struggling Field
   By Richard Jefferys
2. Action Needed Against TB/HIV and the MDR- and XDR-TB Crisis
   By Theo Smart and Javid Syed
3. Palm Project Interviews: A Talk With Steven Deeks
   By Richard Jefferys
4. "Cure for AIDS" Finds New Life Among Scientists and Activists

2007

September 2007
To read PDF, click here

1. Rapidly Progressing Hepatitis C in New York Gay Men
   By Tracy Swan
2. The Sitges Statement on HCV Drug Development
3. Studying New Drugs for HCV: Excerpts From the FDA Hearings
   By Bob Huff
4. Worldwide Antiretroviral Drug Sales 2006
5. Faster TB Test for Resource-Limited Settings
   By Theo Smart
6. Basic Research is a Government Responsibility
   By Robert Siliciano, M.D., Ph.D.
7. Immune Activation in HIV Infection: More Than Just Markers
   By Richard Jefferys

2006

December 2006
To read PDF, click here

1. Activist Chides TB Congress for Complacency in Facing Drug Resistance
   By Theo Smart
2. Tuberculosis Research & Development: A Critical Analysis
3. How We Treat TB Today: A Talk With Gavin Churchyard
   By Mark Harrington
4. TB Transmission in Healthcare Settings
   By Theo Smart
5. Gut Reactions
   By Richard Jefferys
6. Update: Leaking LPS
7. In Brief
8. GRACE Under Pressure
   By Rob Camp
9. Editorial: What's Next? Leadership Lacking in Move From 3x5 to Universal Access
   By Mark Harrington

April 2006
To read PDF, click here

1. SMART Stops Stopping
   By Richard Jefferys
2. HCV at CROI: Growing Chasm Between Bench and Bedside
   By Tracy Swan
3. Overlapping Epidemics: TB, HIV and Viral Hepatitis
   By Tracy Swan
4. TB Diagnostics: A Crisis for People Living With HIV/AIDS Worldwide
   By Javid Syed
5. Co-Receptor Conundrum
   By Richard Jefferys

2005

January 2005
To read PDF, click here

1. Dismal Science: Squandering Public Goodwill and Scarce Research Funds to Boot -- But to What End?
   By Richard Jefferys
2. Well, How Did We Get Here? A Timeline for the Initiation of the RV144 Prime-Boost Trial
   By Richard Jefferys
3. Late 2004 Changes to Federal (DHHS) Treatment Guidelines
4. Caveat Lector, the Sequel: Tangle of Interests and Disclosure Omissions Cracks Authors' Case for Early, Aggressive Treatment
   By Mike Barr
5. Taylor-ed Treatment: Brown University Clinician Leads the Way in Providing Competent Care to Coinfected Injectors
   By Tracy Swan
6. Letters to the Editor

2004

December 2004
To read PDF, click here

1. Truvánadu: Does Gilead's Famed 903 Study Really Show You What They Tell You It Shows?
   By Steven Miles, M.D.
2. Cell Therapy aka Therapeutic "Vaccine" Surprise Announcement for World AIDS Day
   By Mike Barr
3. Project Inform's IX IRTT: Why the Tap 'n' Drainers Have Always Been Wrong; Plus, a New Theory About MDR HIV
   By Richard Jefferys
4. Dogs and Ponies: Mixed Results (and Lots of Diarrhea) for the Tipranavir Studies; Plus Salvage Study Designs for JNJ/Tibotec's PI and Non-Nuke
   By Rob Camp and Mike Barr
5. Who Provides You With Up-to-Date Treatment Information? Popular Treatment Information Resources for Doctors and Patients -- and Their Reliance on Pharmaceutical Largesse

October 2004

1. Treble Damages: Vaccine Scientists Struggle to Come to Grips With the Field's "Berlin"
   By Richard Jefferys
2. Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo
   By Rob Camp
3. Note to Readers/Aviso a Nuestros Lectores en Español
4. Now Available at the TAG Web Site

September 2004
To read PDF, click here

1. The Irony of Bangkok: How to Get 6 Million Poor People on Antiretroviral Therapy -- and 1 Million Rich People Off
2. The Agony of Bangkok: Thai Activist Exhorts Conference Crowd to Stand Firm Against U.S. Patent Regime and "Masks of Fake Concern"
   By Paisan Suwannawong
3. A Call to Arms: Veteran NEJM Editor Takes on Big Pharma as No One Before; Calls for Sweeping Reforms

August 2004
To read PDF, click here

1. TDM, Stat!: More Mixes Nixed By Concentration Preoccupations
   By Yasmin Halima and Rob Camp
2. Continuous HAART and the Law of Diminishing Returns: French Researchers Question Benefit of Lifelong Antiretroviral Treatment
3. Breaking the Silence, v2: Treatment Advocates Strategize At TAG's 2nd Annual International TB/HIV Workshop

July 2004
To read PDF, click here

1. One Step Forward: Merck Vaccine Moves Forward With Efficacy Trial, While Special Committee Tries to Salvage Thai Study
2. Checkmate: French African Study Offers Critical Challenge To Generics Obstructionists
   By Mike Barr
3. Stern Words For Pfizer

June 2004
To read PDF, click here

1. Goodnight, Gracie! Quirky PK of BI's Tipranavir May Confine Its Use to Limited Rescue Role
   By Rob Camp
2. Public Unhealth: Expert Panel's Decision to Recommend Against Routine HCV Screening Draws Community Ire
   By Tracy Swan
3. Response to U.S. Preventative Services Task Force Recommendations on Screening for HCV Infection

May 2004
To read PDF, click here

1. Trust Busting: Abbott, Trimeris/Roche Pricing Decisions Rekindle Old R&D Cost Questions
2. Letters to the Editor
3. Pharmacy by Fiat: Little-Noticed Ban of Little-Used Drug Triggers Little-Known Investigation
   By Dr. Paul C. Bellman

April 2004
To read PDF, click here

1. Peg Elation: XI CROI, Stage for Results of Three Large HCV Treatment Trials
   By Tracy Swan
2. Where's My Pipeline? Vicissitudes of Medicine and Marketing Take Toll on Me-Too Line Up
   By Rob Camp

March 2004
To read PDF, click here

1. Fuzeon Fizzles: Bungled T-20 Launch Claims Its First Casualties, as Losses Spread
   By Mike Barr
2. Crux as Crock: One Shot Immune-Based Therapy Would Be Patient Dream -- and Pharma's Dread
   Interview with Richard Jefferys
3. Seven (Minus 4, Plus 3) Agents to Fix Your Gaze On
   By Rob Camp

February 2004
To read PDF, click here

1. Shot in the Dark: Against the Odds, Immune-Based Therapies for HIV Slog Along
   By Richard Jefferys
2. Blockbusters Beckon: Proliferation of Polymerase Inhibitors and Other Tales From the HCV Crypt
   By Tracy Swan

January 2004
To read PDF, click here

1. Heart of the Matter: To Date, Global Fund Offers Hype and Hope -- But Little Else -- to Majority of Those in Need
   By Richard Stern
2. For Thousands of PWHIVs, Scale Up = Death
   By Richard Stern
3. World AIDS Day in Bolivia: Activists Interrupt Vice Minister of Health at Inauguration Ceremony
4. Holding Court: Activist Meeting With FDA Drugs Division Sets Broad Agenda for Change
   By Rob Camp

2003

December 2003
To read PDF, click here

1. Give 'em Hell, Hogan: Pointers and Prerogatives From and for the Unrepentant Problem Patient
   By Carlton Hogan
2. TAG 2003: The Year at a Glance
3. Past as Prologue: Expediency, Cost-Cutting Trump Science in Peg-Intron Clinical Development Plan
   By Tracy Swan

November 2003
To read PDF, click here

1. Lexiva Launch: Glaxo Makes Aggressive Push Into Protease Market With New and Improved Amprenavir
   By Rob Camp and Heidi Nass
2. Scrambling the Code: What a Difference a Nucleotide Makes -- Plus IL-15's Role Is STI Outcomes
   By Richard Jefferys

October 2003
To read PDF, click here

1. The Diabolic Science: VaxGen's Claims of Vaccine Efficacy Evanesce in Autumn's Last Light
   By Richard Jefferys
2. Medi Gap: Congressional Juggling of Medicare Drug Coverage Leaves Many in the Lurch
3. Letter to President Bush
   By William E. Arnold, Mark Harrington and A. Cornelius Baker

September 2003
To read PDF, click here

1. Rx Americas: Antiretroviral Therapy in Latin America: North of the Southern Cone, a Good Plan Is Hard to Find
   By Richard Stern
2. Tragical Realism: Treatment Coverage for Selected Countries
   By Richard Stern
3. ACTing UP for Treatment Access in Latin America
   By Richard Stern
4. Second Shoe: Doha Dance Has Health Ministries Scheming to Provide Care -- Without Pissing Off Uncle Sam
   By Anne Christine d'Adesky

July 2003
To read PDF, click here

1. Separated at Birth
2. Saturation Point: Latest Licensure Breaks Records for Ho-Hum Reception, yet What Exactly Is There to Be Excited About?
   By Rob Camp
3. Wheat From Chaff: Take-No-Prisoners Tack on TAG Pipeline Report Snubs Host of Drab Wannabes; Cozies up to Fevered Few

June 2003
To read PDF, click here

May 2003
To read PDF, click here

1. Escape From the CTLs: Acute Rx Paradigm Dealt Heavy Blow, While Neutralizing Antibodies Stage a Comeback
   By Richard Jefferys
2. End of an Era: Can a Conference (and an Activist) Outlive Its Utility? A Moment of Unabashed Navel Gazing
   By David Barr
3. TAG at Ten: The Year 2002

April 2003
To read PDF, click here

1. Full Count: Having Sired Twin Failures Hivid and Invirase, Roche Tempts Fate With High Profile T-20 Launch
   By Rob Camp and Matt Sharp
2. Tipping Point: MSF, Oxfam Redefine the Possible, and Y2K Activist Trek to Durban Marks a Watershed
   By David Barr
3. TAG at Ten: The Year 2001

March 2003
To read PDF, click here

1. Magic With Numbers: AIDSVAX Arbitrary and Post-Hoc Subset Analysis, Up Close
2. Under Icebergs' Tip: Tissue T-Cell Analysis Represents Renewed Challenge to "Tap and Drain" Orthodoxy
   By Richard Jefferys
3. Yin and Yang: Yokohama, Vancouver, Twin Pacific Ports, Serve as Polar Opposites for Scientific Advances
   By David Barr
4. Consensus Statement: AIDSVAX Fails to Protect; VaxGen's Claims of Efficacy in Black and Asian Participants Are Misleading and Premature
5. TAG at Ten: The Year 2000

January/February 2003
To read PDF, click here

1. Pushing the Envelope: Critical Issues From TAG's Forthcoming HCV/HIV Co-Infection Report and Analysis
   By Tracy Swan
2. Necessary Diversions: The Boston AIDS Conference That Never Was -- And Other Grim Tales
   By David Barr
3. TAG at Ten: The Year 1999

2002

December 2002
To read PDF, click here

1. Enemies at the Gate: Storming Montréal's Palais de Congrès, and Makeshift Battle Stations in Fortress San Francisco
   By David Barr
2. TAG at Ten: The Year 1998
3. Jabberwocky: Feel Good, "Why Can't We Just All Be Friends?" Executive Reunion Ends in Promises Aplenty
   By Mark Harrington

November 2002
To read PDF, click here

1. Altered States: Nattering Nabobs' Noxious Spin, And the Imperiled Future of STI Research
   By Richard Jefferys
2. TAG at Ten: The Year 1997
3. Marking Time: Commune of Shell Shocked Soldiers Springs Up Then Quickly Crumbles, Inexplicably
   By David Barr

October 2002
To read PDF, click here

1. Double Jeopardy: Series of Superinfection Reports Leave Researchers Debating Not "If" but "How" -- And What It All Means
   By Richard Jefferys
2. Re-Infection Data Summarized
   By Richard Jefferys
3. The Way Forward: Philly ACT UPer and Health Gap Founder Tackles the Challenges of an Aging Activist Movement

September 2002
To read PDF, click here

1. Turn the Beat Around: Disco Queen Née Policy Gadfly Recalls Decade of Seismic Shifts in Clinical Landscape
   By Lynda Dee
2. TAG at 10: The Year 1996
3. Putting It Together: As Scale Up to Rx for 3M by 2005 Proceeds, Activist Groups Worldwide Begin to Lay Groundwork
   By Mark Harrington

July 2002
To read PDF, click here

1. Swindling Siam
   Consensus statement in opposition to licensure of Remune as monotherapy for HIV infection in Thailand
2. Co-Conspirators
   HIV spread threatens decade's tuberculosis treatment/prevention success
3. Guiding Light
   Overwhelming array of variables confounds interpretation of co-infection studies

May 2002
To read PDF, click here

1. Fairy Tale Failure: Studies of PI-Resistant Virus Offer Tantalizing Possibilities for Immune Reconstitution
   By Richard Jeffreys
2. Community Rx: Scrapping Volunteer Model Meant Curtains for Activist Conscripts and Paved Way for TAG Ascendency
   By David Barr
3. TAG at 10: The Year 1995
4. Advocate Finds Harrington's WHO Guideline Comments Refreshing
   By Richard Stern

April 2002
To read PDF, click here

1. Flying the Coop: Giant Prophylactic Enshrouds Senator's Suburban Home; New Era of Inside/Outside Activism Is Born
2. TAG at 10: The Year 1994
3. Suivez La Piste: HIV-Specific CD4 Cell, Holy Grail of Immune Control, Is Hunted Down in Paris Laboratory
   By Richard Jefferys
4. HIV-Specific T-Cell Activity by Fiat? Studies Currently Underway in France
5. Not to Be Sneezed At: Merck's HIV Vaccine Program

March 2002
To read PDF, click here

1. Activism = Hope: TAG Elder/Alumnus Remembers Struggles Past and Present With Humility, Nostalgia, Foreboding
   By Gregg Gonsalves
2. Once We Were Warriors: Activist Corpses Borne in Protest, Furtive Legislative Coups, and the Devastation That Was Berlin
   By Mark Harrington
3. TAG at 10: The Year 1993

January/February 2002
To read PDF, click here

1. Annals of Crisis: A Peek Back at TAG's First Year Shows How Much, and How Little, Has Changed
   By Mark Harrington
2. Revenge of the CTLs: Harvard Vaccine Team Exposes Potential Dark Side of Reliance on Cellular Immune Protection
   By Richard Jeffreys
3. Mobilizing the Troops: Newly International North American Activist Alliance Gathers in Vancouver
   By Mark Baker

2001

November 2001
To read PDF, click here

1. Tenofovir (Viread), First Novel Antiviral Agent in Six Years, Approved by FDA
2. Riddle Women: Reports of Progress Toward Understanding How Some People Appear to Fight Off HIV
   By Richard Jeffreys
3. Studies on Exposed Seronegative Cohorts
4. Patent Politics: Nongovernmental Organization Access Effort Dealt Stealth Blow By Ivy League Development Institute

September 2001
To read PDF, click here

1. Breaking It Down
2. Down the Pike: Argentina International AIDS Society Conference Snoozer Prompts Systematic Review of Drug Pipeline
   By Mark Harrington
3. Shreds of Evidence: Shudda, Cudda, Wudda -- Reevaluating the Treatment Revolution After the Fall
   By David Barr
4. Coming, Going and Gone: The Drug Development Pipeline, 2002

July/August 2001
To read PDF, click here

1. Strike Two: Succumbing to Exhaustion
   By David Barr
2. Drug Economy: Souped-Up Monotherapy
   By Mike Barr
3. Human Leukocyte Antigens (HLA) and HIV Disease Progression

June 2001
To read PDF, click here

1. Vaccine Vitriol: Call for Poor Country Focus on Treatment, Care Programs Elicits Voice of Concern from Vaccine Outfit
   By Mark Harrington
2. African Epistle: Outrage, Indifference Greet Plans for Worldwide Treatment Agenda -- As Millions More Die
   By Mark Harringon
3. Stalled in the Gates: The Not So Accelerated Access Initiative
   By Mark Harringon

April 2001
To read PDF, click here

1. Needleless Retinitis Therapy With FDA Approval of Oral CMV Drug
   
2. FDA Discusses Trial Design for Salvage Therapy
   
3. Brazil 1, Merck 0: The Cost of Generic Drugs in Brazil
   

March 2001
To read PDF, click here

1. Vaccine Advance: Merck Makes Surprise Announcement of Human Vaccine Trial, Currently Underway
   
2. Open Letter to Pharma Execs
   
3. March 5th: Day of Global Direct Action for Drug Access
   

January 2001

1. Pendulum Swing: Treatment Paradigms Come and Go, But the Virus and Its Problematic Potions Appear Intractable
   
2. Simian Success: Vaccine Study Seen as Significant Advance, But Questions Remain About Human Applicability
   
3. Early Indications of What "The Accidental President" Might Do for AIDS
   

2000

December 2000

1. Brazil: What Went Right?
   
2. Glaxo Guts Ghana's Import of Generic Combivir and Prepares for Battle
   
3. Generic Jabberwocky: Quality Control of Brazilian-Made Antivirals
   

September 2000

1. Being There: Durban Delegates Return Stateside, Fired Up and Ready to Jump Back Into the Fray
   
2. African Justice: High Court Official, Openly HIV-Positive, Brings Durban Crowd to Their Feet With Heartfelt Plea for Equity
   
3. Taking it to the Street: Thousands Strong, Fledgling South African Activist Group Sends Tremors Around the Globe
   
4. While You Were Sleeping: An African AIDS Aid Chronology
   

August 2000

1. All The Things You Are: Stephen Matthew Gendin, February 20, 1966 - July 19, 2000
   
2. Call To Arms: Africa to Asia, Caribbean to Kazakhstan, An Explosive Epidemic Said to Threaten Backbone of Civil Society
   
3. Dear Dr. Fauci: Broad Coalition of Organizations Calls on NIH to Devote Resources to Questions of Long-Term Therapy
   
4. Notice Paid: TAG's Hepatitis Project Bears Its First and Future Fruit, Issues Research and Treatment Policy Recommendations
   
5. Hepatitis C Infection Research & Policy Recommendations
   

July 2000

1. Therapeutic Drug Monitoring in HIV Clinical Care
2. What's This About P-Glycoprotein?
3. P-gp and the Drugs It Affects
4. Some Unanswered Questions About Therapeutic Drug Monitoring

June 2000

1. Liver Spot: Progress Is Being Made But Much Remains to Be Done in the Treatment of Hepatitis C Infection
2. Vagina Dialogues: Women-Controlled STD Prevention Methods Take Center Stage in Washington
3. Striking the Balance: Brave New World of Human Gene Sequencing Finds Porous Policy Guidelines to Its Liking

April 2000

1. Bonanza: With Demand for Treatment Breaks at Record Level, Market for Tiny, Uninterpretable Studies Flourishes
   
2. Diminishing Returns: Two-Week Viral Rebounds in Four Swiss Intermittent Treatment Trial (SITT) Patients over the course of Three STIs (Table)
   
3. Research Rut: Beefed Up Federal AIDS Vaccine Program Found to Suffer from Lingering Shortcomings
   
4. Agouron and Immune Response to Bridge Rx Gap
   

March 2000

1. Cohort Studies Suggesting Immediate HAART Confers No Extra Benefit Compared with Deferred HAART in HIV-Infected Persons CD4 >200 cells/mm³ (Table)
2. Behemoth: Eradication's Ebb Finds Researchers Wrestling Again with Clinical Outcome Concerns
3. ART Real World: Observational Databases Promise to Solve Clinical Trials Lag, But Experts Warn All Data Not Created Equal
4. OCS Redux: International Statistical Panel Puts Observational Cohort Study Research Possibilities into Perspective, Identifies Limitations

January 2000

1. Selected Primate Models of HIV Infection (Table)
2. Research Agenda for Treatment Breaks
3. Death by Rx: Where Good Meets Harm
4. Vaccine Notes from the Cent Gardes

1999

September 1999

1. Not So Unforgiving After All? (Table)
2. HIV Immunology: The Road Ahead
3. Toronto: Stirrings of a Treatment Revolution
4. Stopping Therapy: Intriguing New Data

June 1999

1. Data Drought: As Treatment Euphoria Ebbs, Stubborn Uncertainties Resurface But Are Unlikely to Be Resolved
2. Early or Late? Arguments for Immediate Antiretroviral Therapy Versus Delayed Antiretroviral Therapy (Table)
3. Gotcha: HIV Antibody Breakthrough in Transgenic Mice Could Prove Boon to Vaccine Effort
4. Status of Current HIV-1 Vaccine Strategies (Table)

May 1999

1. TAG Community Forum: AIDS Vaccines and Microbicides, the Latest Developments
2. AZT Monotherapy Veteran Checks out Chemotherapeutic Quitsville and Lives to Tell About It
3. Frontiers of Immunology: Thymic Rebound, Naïve CD4+ T-Cell Repopulation Demonstrated in Individuals on HAART
4. T-Cell Kinetics in HIV-Negative and HIV-Infected Individuals (Table)
5. Differences Between Hellerstein and Ho T-Cell Labeling Experiments (Table)
6. Thymic Immigration (Table)

March 1999

1. Researchers and Patients Struggle to Interpret Viral Breakthrough
2. Continual Suppression to Yield to Pulsed Therapy? (sidebar)
3. AIDSVax Field Trial Makes a Splash While Humble Canarypox Phase II Plods Along Uncelebrated
4. Status of Current HIV-1 Vaccine Strategies (Table)

January 1999

1. Scottish Scribe Tells of Resistance Testing Success, Superinfection, Flaws in Dual Protease Regimens
2. At a Glance: South Africa (Table)
3. VIRADAPT: Physician Judgment vs. Genotypic Resistance Results for Treatment Switching Decisions Upon Virologic Rebound (Table)
4. Tidy Clinical Science Stares Down Quotidien Chaos Theory; Might Not "Late, Hard" Be Better After All?

Articles/Reports

• HIV/AIDS-Related Complications (Regularly updated)
• Reviewing Strategies for Draining HIV Reservoirs (April 12, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Countervailing Selective Forces Shape HIV (April 9, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Can a Route to Broadly Neutralizing Antibodies Be Traced? (April 4, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Probiotic/Prebiotic Supplement Combination Shows Benefits in SIV-Infected Pigtailed Macaques (March 25, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Gene Modification of Virus-Specific CD4 T Cells (March 25, 2013)
  Selected research highlight from CROI 2013.
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Engineering SIV to Spare the CD4 T Cell Help (March 25, 2013)
  Selected research highlight from CROI 2013.
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• CMV Vector Vaccination Leads to Apparent Clearance of SIV Infection (March 25, 2013)
  Selected research highlight from CROI 2013.
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Results From Multi-Dose Vorinostat Trial (March 25, 2013)
  Selected research highlight from CROI 2013.
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Curing HIV Removes the Scars of the Past (March 25, 2013)
  Selected research highlight from CROI 2013.
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Report of a Functional Cure in an HIV-Infected Infant (March 6, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• CD4 T Cells Specific for Different Pathogens Vary in Susceptibility to HIV Infection (February 6, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Revitalizing T Cells by Blocking PD-L1 (January 29, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Australian AIDS Cure Claim Leads to a Maelstrom of Hype and Misinformation (January 29, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• David Baltimore and Vectored Immunoprophylaxis (January 18, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Dendritic Cell-Based Therapeutic HIV Vaccine Transiently Modulates Viral Load (January 15, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Lymph Node Fibrosis, CD4 T Cells, and Immune Reconstitution (January 7, 2013)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• New Research on Gut CD4 T Cell Depletion and HIV Pathogenesis (December 31, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• HIV Replication and Persistence in T Follicular Helper Cells (December 31, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Attack of the Killer Helpers (Part Two) (November 27, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• T Follicular Helper Cells and HIV (November 26, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Dodging HIV Variability by Targeting HERVs (November 14, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Posttreatment Control of HIV Replication and Prospects for a Functional Cure (October 17, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Webcasts and Abstracts From the AIDS Vaccine 2012 Conference (September 14, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Quantifying HIV-1 Exposure to Illuminate Resistance to Infection (September 12, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Immune Activation, Inflammation and HIV Acquisition Risk (August 21, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Cure-Related Research at AIDS 2012 (August 13, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Hopes Raised by HDAC Inhibitor, but Uncertainties Remain (July 27, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Antiviral Activity of Virus-Specific CD8 T Cells Linked to Rate of CD4 T Cell Decline in HIV Infection (July 26, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• HIV i-Base/Treatment Action Group 2012 Pipeline Report Reveals Deep Gaps Between Scientific Promise and Program Delivery (July 21, 2012)
  Recent advances in biomedical HIV, hepatitis C virus (HCV) and tuberculosis (TB) prevention and treatment are not reaching those who need them most; political leaders continue to break domestic, global health commitments.
• 2012 Pipeline Report: HIV, Hepatitis C Virus (HCV) and Tuberculosis Drugs, Diagnostics, Vaccines and Preventive Technologies in Development (PDF) (July 2012)
• Role of Cell-to-Cell Transmission in Sustaining the HIV Reservoir (June 29, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• New Data on the Berlin Patient: Interpret With Caution (June 9, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Enhanced HIV Acquisition Risk in the STEP Study Wanes Over Time (May 4, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Behavior and Circumcision Status Do Not Explain Increased Risk of HIV Acquisition Associated With Ad5-Based Vaccine (April 20, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• HIV-Killing Stem Cell Paper Glosses Over Key Caveat (April 20, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Study of HIV Superinfection and Neutralizing Antibody Responses Causes Confusion (April 16, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Incivek (Telaprevir) Fact Sheet (April 2012)
  To read PDF, click here
• Victrelis (Boceprevir) Fact Sheet (April 2012)
  To read PDF, click here
• Study Questions Role of HDAC Inhibitors in HIV Cure Research (March 30, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Inching Forward With HIV Vaccines: Digesting Envelope Decoys (March 21, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• 19th Conference on Retroviruses & Opportunistic Infections (March 14, 2012)
  In Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog
• Community HIV Cure Workshop (PDF) (March 4, 2012)
  From AIDS Treatment Activists Coalition, Project Inform and Treatment Action Group
• Report and Commentary from the Fifth International Workshop on HIV Persistence During Therapy (February 2012)
• HIV Cure-Related Clinical Research Workshop (October 2011)
• 2011 Pipeline Report: HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development (PDF) (September 2011)
• The Antiretroviral Pipeline (September 2011)
• The Pediatric Antiretroviral Pipeline (September 2011)
• HIV Point of Care Diagnostics Pipeline (September 2011)
• Patents and the Pipeline: Is Access Under Threat? (September 2011)
• Preventive Technologies, Immune-Based and Gene Therapies and Research Toward a Cure (September 2011)
• The Hepatitis C Treatment Pipeline (September 2011)
• Scholarships for Activists: What Would You Do for the Cure? An AIDS Community Challenge (August 24, 2011)
• Guide to Clinical Trials for People With Hepatitis C (August 2011)
• The Hepatitis C Treatment Pipeline Report (March 2011)
  To read PDF, click here.
• Request for Organizational Sign-On: Release U.S. Funding for Global Harm Reduction (June 17, 2010)
• Join a Rally in Washington, D.C., on May 19 to Call for Hepatitis Program Funding (April 30, 2010)
• Bananas Over BanLec (March 16, 2010)
• A Letter to President Obama (November 18, 2009)
• Cause for Caution on the Results of the ALVAC/AIDSVAX HIV Vaccine Efficacy Trial: More Marginal Than "Modest" (September 25, 2009)
• Antiretroviral Drug Development in 2009 (July 2009)
  To read PDF, click here
• TAG 2009 Pipeline Report (PDF) (July 2009)
• Tell Congress to Make Health Care Reform Work for People With HIV/AIDS! (June 19, 2009)
• Guide to Hepatitis B for People Living With HIV (June 2009)
  To read PDF, click here.
• Flat-Lined: How Flat NIH Funding Undermines Research on HIV, Tuberculosis, and Viral Hepatitis (PDF) (May 2009)
• Tuberculosis Research & Development: A Critical Analysis of Funding Trends, 2005?2007: An Update (PDF) (May 2009)
• TAG's Response to NIAID "Request for Information" on Priorities in Basic HIV Vaccine Research (June 4, 2008)
• PAVE Gives Pause: Position Statement on the Proposed PAVE100A Vaccine Trial (May 30, 2008)
• Updated, Annotated Preventive Vaccine Pipeline Table (May 29, 2008)
  Information on the current preventive HIV vaccine pipeline, annotated with commentary and links to published and presented data.
• Hepatitis C: New Treatments in the Pipeline (April 2008)
  To read PDF, click here
• Opinion: TB Striking Back With a Vengeance; Need for Research Funds Grows Urgent (Winter 2007)
  To read PDF, click here
• Guide to Hepatitis C for People Living With HIV (August 2007)
  Testing, coinfection, treatment and support
  To read PDF, click here
• Access to Hepatitis C Treatment Through State AIDS Drug Assistance Programs (ADAPs) (May 31, 2007)
• Sitges Statement on HIV/HCV Coinfection (May 18, 2007)
• Notes From the NIAID Workshop on Immune Activation and HIV Pathogenesis (May 18, 2007)
• Treatment Action Group Supports Maraviroc Approval (May 1, 2007)
• 2007 Antiretrovirals in Development Pipeline (March 23, 2007)
  To read PDF, click here
• Palm Project Interview Series: Douglas Nixon (February 8, 2007)
• Palm Project Interview Series: Steven Deeks (February 8, 2007)
• TMC114/r (darunavir/r, Prezista): Who's got the POWER? (May 25, 2006)
• AIDS Activism, Boehringer Ingelheim and the Broken Social Contract (April 21, 2006)
  To read PDF, click here
• Treatment Action Group Statement on the Termination of the SMART Study (January 18, 2006)
  To read PDF, click here
• Immune-Based Therapies and Preventive Technologies Pipeline (September 29, 2005)
  To read PDF, click here
• The Hepatitis C Virus (HCV) Treatment Pipeline (September 26, 2005)
  To read PDF, click here
• Lactic Acidosis (September 19, 2005)
• The Tuberculosis (TB) Treatment Pipeline (July 2005)
• TAG Testimony to the FDA Vaccines and Related Biological Products Advisory Committee (September 28, 2004)
  Regarding the U.S. Military/NIAID-sponsored RV144 ALVAC/AIDSVAX "Prime-Boost" vaccine trial in Thailand
• Position Paper on 908 (Fosamprenavir, Lexiva) (October 13, 2003)
  To read PDF, click here
• Position Paper on Atazanavir (BMS-232623, Reyataz) (July 23, 2003)
• Fuzeon Brand Enfuvirtide (T-20): Breaking Barriers or Breaking the Bank? (March 7, 2003)
• Research and Policy Recommendations for HCV/HIV Coinfection (February 2003)
  To read PDF, click here
• January/February 2003 Basic Science Review (January/February 2003)
• Swiss-Spanish Intermittent Treatment Trial Downer (January 29, 2003)
• September 2002 Basic Science Review (September 2002)
• Updates From Retrovirus 2002: Basic Science and Vaccines (April 9, 2002)
• Coming, Going and Gone: The Drug Development Pipeline, 2002 (March 12, 2002)
• The Promise of New Vaccine Vectors, the Perils of Partial Protection (March 1, 2002)
  Two new HIV vaccine studies published in the journal Nature
• What's in Glaxo's HIV Vaccine? (March 1, 2002)
• Comments on Problems in the Current Draft World Health Organization (WHO) Antiretroviral Treatment Guidelines for Resource Limited Settings (March 2002)
  By Mark Harrington
• To Double, or Not to Double? Bioterror Buys a Budget Boost (February 2002)
  By Mark Harrington
• Activists Call for Immediate Approval of Viread™ Tenofovir DF (October 3, 2001)
• Position Paper on NDA 21-356 for Gilead Sciences' Viread™ Brand Tenofovir Disoproxil Fumarate (October 3, 2001)
• Ten Texts on Saquinavir: Its Rapid Rise and Fall (PDF) (June 16, 2001)
  By Mark Harrington
• A Critical Review of the Research and Treatment of Hepatitis C Virus (HCV) and Hepatitis & HIV Coinfection (July 9-14, 2000)
  By Michael Marco and Jeffrey Schouten
• Exploring the American Response to the Global AIDS Pandemic (Summer 2000)
• Problems With Protease Inhibitor Development Plans (February 23, 1995)
• THE KS PROJECT REPORT: Current Issues in Research and Treatment of Kaposi's Sarcoma (July 25, 1994)
  By Michael Marco, with Martin Majchrowicz; forward by Susan E. Krown, M.D.
• The Crisis in Clinical AIDS Research (December 1, 1993)
  By Mark Harrington
• Basic Research on HIV Infection: A Report From the Front (June 1, 1993)

En Español

• Incivek (Telaprevir) (abril de 2012)
  Ver PDF.
• Victrelis (Boceprevir) (abril de 2012)
  Ver PDF.
• Guía de la Hepatitis B Para Personas Que Viven Con VIH (junio de 2009)
  Ver PDF.